Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Included in the shares are 840,000 shares sold by Alnylam pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Alnylam’s common stock is listed on NASDAQ under the symbol “ALNY.”
Headquartered in Cambridge, Massachusetts, and founded in 2002, Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associate Dan Gibbons. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. The tax team included partner Michael Farber and associates Isaac Macdonald and Gil Savir. Members of the Davis Polk team are based in the New York and Northern California offices.